{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:54:19Z","timestamp":1790970859211,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["818715"],"award-info":[{"award-number":["818715"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cardior Pharmaceuticals GmbH"},{"name":"NovoNordisk"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cardior Pharmaceuticals GmbH"},{"name":"NovoNordisk"},{"DOI":"10.13039\/501100001826","name":"ZonMW","doi-asserted-by":"publisher","award":["04510012210034"],"award-info":[{"award-number":["04510012210034"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMW","doi-asserted-by":"publisher","award":["NWO-VENI"],"award-info":[{"award-number":["NWO-VENI"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMW","doi-asserted-by":"publisher","award":["09150162310159"],"award-info":[{"award-number":["09150162310159"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016262","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cardior Pharmaceuticals GmbH"},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The Framingham risk score (FRS), a tool primarily used for atherosclerotic cardiovascular disease (ASCVD) risk stratification, incorporates factors like age, obesity, and smoking. However, its role in predicting cancer and heart failure (HF) risk remains unclear, while emerging data suggest these two conditions coincide frequently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a post hoc analysis using data from the PREVEND study and validated our findings in the UK Biobank. We examined the association between FRS tertiles at baseline and incident cancer or HF. Fine\u2013Gray regression models were used to calculate subdistribution hazard ratios (sHRs), adjusting for estimated glomerular filtration rate and urinary albumin excretion with all-cause mortality as a competing risk. In PREVEND, we included 8123 participants (mean age 49 \u00b1 13 years, 50% female). Over follow-up periods of 17.46 years [interquartile range (IQR) 17.15\u201317.80] (cancer) and 23.39 years (IQR 13.78\u201323.81) (HF), 1176 participants developed new-onset cancer and 758 developed new-onset HF. In a multivariable analysis, participants in the highest FRS tertile compared with the lowest had a higher hazard for both cancer (sHR 2.32, P &amp;lt; 0.001) and HF (sHR 10.08, P &amp;lt; 0.001). Participants in the highest FRS tertile also had the worst survival (log-rank P &amp;lt; 0.001). We validated these findings in the UK Biobank (n = 389942) wherein individuals in the highest FRS tertile also had a higher hazard for both cancer (sHR 2.05, P &amp;lt; 0.001) and HF (sHR 5.99, P &amp;lt; 0.001) compared with the lowest tertile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The FRS associates with new-onset cancer or HF, implicating a broader clinical application of the FRS beyond ASCVD risk stratification in cardio-oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf618","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:08:37Z","timestamp":1758888517000},"page":"490-497","source":"Crossref","is-referenced-by-count":5,"title":["Framingham risk score associates with incident cancer and heart failure"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1764-0242","authenticated-orcid":false,"given":"Pieter F","family":"van den Berg","sequence":"first","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura I","family":"Yousif","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-0859","authenticated-orcid":false,"given":"Yvonne","family":"Koop","sequence":"additional","affiliation":[{"name":"Cardiovascular Epidemiology, Julius Centre for Health Sciences and Primary Care, Utrecht University Medical Centre, Utrecht University , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi Hatip","family":"\u00dcnl\u00fc","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melis","family":"Asik","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J","family":"van Essen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Centre Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-2228","authenticated-orcid":false,"given":"Kevin","family":"Damman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Centre Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A","family":"Voors","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Centre Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil V","family":"Sayour","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Semmelweis University , Budapest ,","place":["Hungary"]},{"name":"Gottsegen National Cardiovascular Centre , Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F","family":"Kok","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqian","family":"Yang","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-9745","authenticated-orcid":false,"given":"Isabella","family":"Kardys","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3356-6791","authenticated-orcid":false,"given":"Stephan J L","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nephrology Division, University Medical Centre Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"van der Vegt","sequence":"additional","affiliation":[{"name":"Department of Pathology and Medical Biology, University Medical Centre Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Suthahar","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A","family":"de Boer","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3287-6766","authenticated-orcid":false,"given":"Wouter C","family":"Meijers","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, 3015GD , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"2026031311371826800_zwaf618-B1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","article-title":"Cardiovascular disease and cancer: shared risk factors and mechanisms","volume":"21","author":"Wilcox","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026031311371826800_zwaf618-B2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026031311371826800_zwaf618-B3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2023.04.018","article-title":"Chapter 1: the burden of heart failure","volume":"137","author":"Pratley","year":"2024","journal-title":"Am J Med"},{"key":"2026031311371826800_zwaf618-B4","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1093\/cvr\/cvac132","article-title":"Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies","volume":"118","author":"de Wit","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026031311371826800_zwaf618-B5","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/eurheartj\/ehae105","article-title":"Heart failure pharmacotherapy and cancer: pathways and pre-clinical\/clinical evidence","volume":"45","author":"Sayour","year":"2024","journal-title":"Eur Heart J"},{"key":"2026031311371826800_zwaf618-B6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaccao.2021.11.007","article-title":"Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort","volume":"4","author":"Bertero","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026031311371826800_zwaf618-B7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.472","article-title":"Incidence of cancer in patients with chronic heart failure: a long-term follow-up study","volume":"18","author":"Banke","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026031311371826800_zwaf618-B8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gheart.2013.01.001","article-title":"Cardiovascular disease risk assessment: insights from Framingham","volume":"8","author":"D\u2019Agostino","year":"2013","journal-title":"Glob Heart"},{"key":"2026031311371826800_zwaf618-B9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ahj.2007.02.027","article-title":"Prediction of first coronary events with the Framingham score: a systematic review","volume":"153","author":"Eichler","year":"2007","journal-title":"Am Heart J"},{"key":"2026031311371826800_zwaf618-B10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.ajkd.2012.06.017","article-title":"Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (prevention of renal and vascular endstage disease) study","volume":"60","author":"Smink","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2026031311371826800_zwaf618-B11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/CIRCULATIONAHA.122.059663","article-title":"Association between device-measured physical activity and incident heart failure: a prospective cohort study of 94 739 UK Biobank participants","volume":"146","author":"Ho","year":"2022","journal-title":"Circulation"},{"key":"2026031311371826800_zwaf618-B12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41416-022-02053-5","article-title":"UK Biobank: a globally important resource for cancer research","volume":"128","author":"Conroy","year":"2023","journal-title":"Br J Cancer"},{"key":"2026031311371826800_zwaf618-B13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1155\/2007\/971816","article-title":"Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Anal Cell Pathol"},{"key":"2026031311371826800_zwaf618-B14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaccao.2023.03.015","article-title":"Fibrotic marker galectin-3 identifies males at risk of developing cancer and heart failure","volume":"5","author":"van den Berg","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026031311371826800_zwaf618-B15","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/eurheartj\/ehae868","article-title":"Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years","volume":"46","author":"van Essen","year":"2024","journal-title":"Eur Heart J"},{"key":"2026031311371826800_zwaf618-B16","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"2026031311371826800_zwaf618-B17"},{"key":"2026031311371826800_zwaf618-B18","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1161\/CIRCULATIONAHA.108.816694","article-title":"Predicting the 30-year risk of cardiovascular disease","volume":"119","author":"Pencina","year":"2009","journal-title":"Circulation"},{"key":"2026031311371826800_zwaf618-B19","doi-asserted-by":"crossref","first-page":"e030234","DOI":"10.1136\/bmjopen-2019-030234","article-title":"Can risk be predicted? An umbrella systematic review of current risk prediction models for cardiovascular diseases, diabetes and hypertension","volume":"9","author":"Lucaroni","year":"2019","journal-title":"BMJ Open"},{"key":"2026031311371826800_zwaf618-B20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2016.2050","article-title":"Contributions of the Framingham Heart Study to the epidemiology of coronary heart disease","volume":"1","author":"Chen","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026031311371826800_zwaf618-B21","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: associations and relations","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026031311371826800_zwaf618-B22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"2026031311371826800_zwaf618-B23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaccao.2024.05.015","article-title":"Predictive performance of cardiovascular risk scores in cancer survivors from the UK Biobank","volume":"6","author":"McCracken","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026031311371826800_zwaf618-B24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"2026031311371826800_zwaf618-B25","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the translational research committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026031311371826800_zwaf618-B26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.15420\/cfr.2019.1.2","article-title":"Bidirectional relationship between cancer and heart failure: old and new issues in cardio-oncology","volume":"5","author":"Bertero","year":"2019","journal-title":"Card Fail Rev"},{"key":"2026031311371826800_zwaf618-B27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1161\/CIRCULATIONAHA.118.033603","article-title":"Linking heart failure to cancer","volume":"138","author":"Bertero","year":"2018","journal-title":"Circulation"},{"key":"2026031311371826800_zwaf618-B28","doi-asserted-by":"crossref","first-page":"13185","DOI":"10.3390\/ijms252313185","article-title":"The complex connection between myocardial dysfunction and cancer beyond cardiotoxicity: shared risk factors and common molecular pathways","volume":"25","author":"Moln\u00e1r","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026031311371826800_zwaf618-B29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/CIRCRESAHA.124.325490","article-title":"Insights into heart-tumor interactions in heart failure","volume":"136","author":"Caller","year":"2025","journal-title":"Circ Res"},{"key":"2026031311371826800_zwaf618-B30","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/eurjpc\/zwae089","article-title":"Association of inflammatory markers with incident heart failure or cancer in the HUNT3 and health ABC population studies","volume":"31","author":"Bertero","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026031311371826800_zwaf618-B31","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.freeradbiomed.2012.02.035","article-title":"Emerging avenues linking inflammation and cancer","volume":"52","author":"Kundu","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"2026031311371826800_zwaf618-B32","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2174\/1381612827666210303143442","article-title":"Chronic inflammation and cancer: the role of endothelial dysfunction and vascular inflammation","volume":"27","author":"Malhab","year":"2021","journal-title":"Curr Pharm Des"},{"key":"2026031311371826800_zwaf618-B33","doi-asserted-by":"crossref","first-page":"11786","DOI":"10.3390\/ijms241411786","article-title":"Atherosclerosis, diabetes mellitus, and cancer: common epidemiology, shared mechanisms, and future management","volume":"24","author":"Katsi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026031311371826800_zwaf618-B34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-020-1961-1","article-title":"Tobacco smoking and somatic mutations in human bronchial epithelium","volume":"578","author":"Yoshida","year":"2020","journal-title":"Nature"},{"key":"2026031311371826800_zwaf618-B35","doi-asserted-by":"crossref","first-page":"19480","DOI":"10.1038\/s41598-020-76556-7","article-title":"The effect of smoking on chronic inflammation, immune function and blood cell composition","volume":"10","author":"Elisia","year":"2020","journal-title":"Sci Rep"},{"key":"2026031311371826800_zwaf618-B36","doi-asserted-by":"crossref","first-page":"103177","DOI":"10.1016\/j.critrevonc.2020.103177","article-title":"Chronic inflammation towards cancer incidence: a systematic review and meta-analysis of epidemiological studies","volume":"157","author":"Michels","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026031311371826800_zwaf618-B37","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1093\/eurheartj\/ehz587","article-title":"The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study","volume":"40","author":"van\u2019t Klooster","year":"2019","journal-title":"Eur Heart J"},{"key":"2026031311371826800_zwaf618-B38","doi-asserted-by":"crossref","first-page":"e0325287","DOI":"10.1371\/journal.pone.0325287","article-title":"Association between inflammatory burden index and prognosis in patients with coronary heart disease: a retrospective study","volume":"20","author":"Lu","year":"2025","journal-title":"PLoS One"},{"key":"2026031311371826800_zwaf618-B39","doi-asserted-by":"crossref","first-page":"25034","DOI":"10.1038\/s41598-025-09574-y","article-title":"Inflammatory burden index predicts long term mortality in a nationally representative population from NHANES","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"2026031311371826800_zwaf618-B40","doi-asserted-by":"crossref","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy\u2013related cardiac dysfunction and heart failure","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026031311371826800_zwaf618-B41","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"2026031311371826800_zwaf618-B42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4082\/kjfm.2016.37.4.235","article-title":"Risk of cardiovascular disease using Framingham risk score in Korean cancer survivors","volume":"37","author":"So","year":"2016","journal-title":"Korean J Fam Med"},{"key":"2026031311371826800_zwaf618-B43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-018-4723-0","article-title":"The risk of cardiovascular disease following breast cancer by Framingham risk score","volume":"170","author":"Gernaat","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2026031311371826800_zwaf618-B44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11936-024-01033-7","article-title":"Program building in cardio-oncology: bridging existing care gaps to improve cardiovascular and cancer outcomes","volume":"26","author":"Manla","year":"2024","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026031311371826800_zwaf618-B45","doi-asserted-by":"crossref","first-page":"10617","DOI":"10.3390\/ijms231810617","article-title":"Cardio-oncology: mechanisms, drug combinations, and reverse cardio-oncology","volume":"23","author":"Liang","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf618\/64418716\/zwaf618.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/4\/490\/64418716\/zwaf618.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/4\/490\/64418716\/zwaf618.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:37:28Z","timestamp":1773416248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/4\/490\/8266911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,27]]},"published-print":{"date-parts":[[2026,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf618","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,27]]}}}